Ngwe Yin
Endocrinology, Diabetes & Metabolism · Fresno, CANPI 1912344672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $696 and has fallen 96.2% since, to $26 in 2023. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 55 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$196
- AbbVie$120
- Abbott$84
- Novo Nordisk$84
- AstraZeneca$81
- Mannkind Corporation$79
- plus $662 from 15 others
What the payments were for
- Food & beverage$1,24795%
- Gifts$595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 4 | $196 |
| AbbVie | 1 | $120 |
| Abbott | 5 | $84 |
| Novo Nordisk | 5 | $84 |
| AstraZeneca(2 entities) | 5 | $81 |
| Mannkind Corporation | 2 | $79 |
| Insulet Corporation | 4 | $77 |
| Dexcom, Inc. | 4 | $71 |
| Corcept Therapeutics | 2 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Ipsen Biopharmaceuticals, Inc | 3 | $67 |
| IBSA Pharma Inc. | 3 | $65 |
| Lilly USA, LLC | 4 | $54 |
| Nevro Corp. | 1 | $45 |
| Eisai Inc. | 2 | $32 |
| Amgen | 1 | $23 |
| Medtronic | 1 | $19 |
| Lifescan, Inc. | 1 | $19 |
| BD | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$125
- Synthroid$120
How this compares
$1,306 in reported general payments places this provider in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 72 | $98,663 |
| HumalogInsulin Lispro | 60 | $18,237 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $10,911 |
| Glucagon Emergency KitGlucagon | 27 | $7,718 |
| Insulin Glargine-Yfgn | 61 | $6,156 |
| Levothyroxine Sodium | 215 | $3,956 |
| Methimazole | 198 | $3,422 |
| Hydrocortisone | 48 | $2,711 |
| Testosterone | 30 | $2,358 |
| Raloxifene Hcl | 16 | $737 |
| Veo Insulin SyringeSyringe-Needle,insulin,0.5 Ml | 21 | $711 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 28 | $575 |
| Cinacalcet Hcl | 13 | $458 |
| Spironolactone | 11 | $412 |
| Alendronate Sodium | 23 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Humalog | $54 | $116,900132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Fresno
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.